CClinicalTrials.gg
Status unknownNCT04750044Updated Oct 26, 2022

Refeeding in Post-ERCP Pancreatitis

An interventional study of early refeeding and delayed refeeding in Post-ERCP Pancreatitis, sponsored by Yonsei University. Status unknown at 9 sites in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Yonsei University · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Endoscopic retrograde cholangio-pancreatography (ERCP) is the most commonly used technique for diagnosis and treatment in the treatment of bile duct diseases including bile duct cholelithiasis and malignant/benign biliary obstruction. In particular, ERCP is an essential procedure for the removal of bile duct gallstones and bile drainage in malignant/benign biliary obstruction patients.

Among ERCP-related complications, especially "post-ERCP pancreatitis (PEP)", which occurs due to the anatomical structure of the pancreatic biliary system, statistically occurs in about 5-10% of patients who first received ERCP. It is known, and treatment for PEP is the same as treatment for general acute pancreatitis but is known to have a relatively worse prognosis.

The basis of treatment for acute pancreatitis is a conservative treatment based on fasting and fluid treatment, and starting oral diet after abdominal pain and pancreatic enzyme levels (amylase/lipase) normalized. However, a recent study reported that early oral diet could improve the patient's prognosis. According to a systematic review of 11 randomized trial papers by Valerie et al., it was reported that the early diet had the effect of reducing hospital stay without increasing adverse events when comparing the prognosis of the early refeeding group and delayed refeeding group. This result is theoretically considered to be because the oral diet has the advantage of increasing intestinal permeability, gut motility and reducing the likelihood of pancreatic necrosis/ infection compared to the parenteral diet.

As above, PEP has the same treatment method as general acute pancreatitis but is known to have a relatively worse prognosis. However, the effect of an early diet recently attempted in acute pancreatitis has not been reported in patients with PEP. Therefore, we investigate the effects of early and delayed diets on the prognosis of patients with PEP through a prospective multicenter study.

Read the detailed description
  1. Selection of research subjects A total of 80 patients, who have occurred pancreatitis after ERCP, will be enrolled at Yonsei University Sinchon Severance Hospital, Seoul National University Hospital, Dongguk University Ilsan Hospital, Gachon University Gil Hospital, Gyeongsang National University Changwon Hospital, Kyungpook National University Hospital, Seoul St. Mary's Hospital, Korea University Ansan Hospital, Pusan National University Hospital. The purpose and contents of this clinical trial are informed in detail to the subject and consent is obtained.
  2. Evaluation of eligibility Eligibility is determined based on the basic patient data including physical examination, vital signs, body measurements, medical history, concomitant drugs, laboratory tests, and other basic examinations made at the first visit.
  3. Grouping and randomization After ERCP was performed, the study subjects who were judged to have PEP according to enroll criteria were divided into early and delayed refeeding groups using a random number table and assigned 1:1 to proceed with the study.
  4. Timing of refeeding In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.

    In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.

  5. Interruption of refeeding In both early and delayed refeeding groups, the oral diet is stopped when the pain scale the patient complains after starting oral diet increases to VAS 5 points or more, or the patient refuses to eat due to abdominal pain or other reasons. The diet is restarted after the amylase/lipase level decreases below the upper normal limit, the patient's pain has disappeared, and the bowel movement is restored.
  6. Dropout criteria

    1. In the case of delayed diet group when symptoms persist for more than 96 hours and cannot start a diet
    2. When fasting is necessary for other reason, such as an imaging test or endoscopy
    3. When it is determined that a parenteral diet is necessary for reasons such as difficulty swallowing
    4. When the researcher judged that the clinical trial cannot be continued
  7. Discharge criteria and hospitalization period for PEP If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP".
02

Conditions studied

  • Post-ERCP Pancreatitis

Browse trials for

03

In context

Pancreatitis

752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 448 interventional studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,387 studies on the registry; 232 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients aged 20 to 80
  2. As patients who developed pancreatitis after receiving ERCP, the following must be satisfied at the same time.

    1. increased serum amylase or lipase 3 times higher than the normal range, at 4 hours after ERCP or the morning of the following day,
    2. New or worsening abdominal pain compatible with pancreatitis, arising 4 hours after ERCP or the next morning

Exclusion criteria

Exclusion Criteria:

  1. If the intended procedure is not completed
  2. If complications such as abdominal perforation or bleeding have occurred or are suspected
  3. If it is judged as severe acute pancreatitis with multi-organ failure la.
  4. When PEP has occurred, but additional imaging tests and endoscopy for diagnosis of the underlying disease or treatment of complications of the patient are required, and fasting is necessary regardless of this study
  5. Patients with a history of chronic pancreatitis
  6. Pregnant women, lactating women
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    early refeeding group

    In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.

    Other: early refeeding

  • Active comparator
    delayed refeeding group

    In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.

    Other: delayed refeeding

Interventions

  • Otherearly refeeding

    In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.

  • Otherdelayed refeeding

    In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.

06

What researchers measure

Primary outcomes

  1. hospitalization period for PEP

    If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP".

    Time frame: up to 1 month

Secondary outcomes

  1. Incidence of acute severe pancreatitis

    comparing rate of incidence of severe acute pancreatitis

    Time frame: up to 1 month

  2. readmission rate (<30 days)

    comparing readmission rate of each group until 30 days after discharge

    Time frame: up to 1 month

  3. mortality rate

    comparing mortality rat of each group during hospitalization

    Time frame: up to 1 month

  4. complication rate

    comparing complication rate including nausea/vomiting, recurrent abdominal pain, necrotizing pancreatitis of each group during hospitalization

    Time frame: up to 1 month

07

Study locations

9 of 9 sites recruiting
  • Korea University Ansan Hospital
    Ansan-si, Korea, Republic of
    • Jung Wan Choe · Contact
    Recruiting
  • Pusan National University Hospital
    Busan, Korea, Republic of
    • Sung Yong Han · Contact
    Recruiting
  • Gyeongsang National University Changwon Hospital
    Changwon, Korea, Republic of
    • Jae Min Lee · Contact
    Recruiting
  • Kyungpook National University School of Medicine
    Daegu, Korea, Republic of
    • Dong Kee Jang · Contact
    Recruiting
  • Gachon University College of Medicine
    Incheon, Korea, Republic of
    • Eui Joo Kim · Contact
    Recruiting
  • Yonsei University College of Medicine
    Seoul, 03722, Korea, Republic of
    Recruiting
  • Seoul Metropolitan Government Boramae Medical Center
    Seoul, Korea, Republic of
    • Dong Kee Jang · Contact
    Recruiting
  • Seoul National University Hospital
    Seoul, Korea, Republic of
    • Sang Hyub Lee · Contact
    Recruiting
  • Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
    • Young Hoon Choi · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04750044
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Feb 11, 2021
Start date
Feb 18, 2021
Primary completion
Nov 10, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Oct 26, 2022

Study contacts

Jung Hyun Jo
Contact
junghyunjo83@yuhs.ac
+82-2-2228-2274
Jung Hyun Jo
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion